Spherix Global Insights

Spherix Global Insights is a privately held market intelligence and advisory firm dedicated to the global life sciences industry. Founded in 2015 by Jennifer and Kevin Robinson, the company is headquartered in Exton, Pennsylvania. Its core mission is to provide strategic guidance and unbiased insights, enabling pharmaceutical companies to make informed decisions and facilitate the delivery of crucial treatments to patients.

Spherix Global Insights offers a comprehensive suite of market research, business intelligence, and advisory services. The firm specializes in several therapeutic areas, including dermatology, gastroenterology, nephrology, neurology, rheumatology, ophthalmology, and hematology/oncology. Key offerings include continuous market intelligence products like RealTime Dynamix™ and Market Dynamix™, launch benchmarking with Launch Dynamix™, patient journey insights via Patient Chart Dynamix™, and market access intelligence through Benefit Design Dynamix™ and Patient Services Dynamix™. These services leverage a proprietary network of specialty physicians to provide deep, commercially relevant analyses.

In recent developments, Dan Barton was appointed CEO in September 2023, with founder Jennifer Robinson transitioning to the board of directors. The company received an investment from Susquehanna Private Capital in January 2022, underscoring its growth trajectory. Spherix Global Insights has expanded its offerings, launching a new client portal in 2023 to enhance access to its research and insights, and extending its services to the financial sector in September 2024 to provide asset managers and hedge funds with critical pharmaceutical market intelligence. In March 2026, the company further broadened its capabilities with a new Market Access suite of services.